Voranigo® (Vorasidenib) Wins Prestigious Prix Galien Awards Across Multiple Regions Voranigo® (vorasidenib) has garnered several Prix Galien awards acknowledging its significant contributions to orphan disease therapies. Discover its journey and innovations.

Voranigo® (Vorasidenib) Wins Prestigious Prix Galien Awards Across Multiple Regions #France #Vorasidenib #Suresnes #VORANIGO #Prix_Galien

Servier's Voranigo® Achieves Multiple Prix Galien Awards for Glioma Treatment Voranigo® has received prestigious Prix Galien Awards in the USA, Poland, and for Bridges, recognizing its impact on patients with glioma.

Servier's Voranigo® Achieves Multiple Prix Galien Awards for Glioma Treatment #France #Servier #Suresnes #VORANIGO #Prix_Galien

Servier Showcases Leadership in Research at 2025 SNO Congress on IDH-Mutant Gliomas At the SNO Congress, Servier presents critical findings from studies focusing on IDH-mutant gliomas, highlighting advancements in cancer treatment and trial methodologies.

Servier Showcases Leadership in Research at 2025 SNO Congress on IDH-Mutant Gliomas #United_States #IDH-mutant_glioma #Honolulu #Servier #VORANIGO

Servier Unveils Encouraging Extended Results for VORANIGO Trial in Glioma Treatment Recent findings from the extended analysis of the INDIGO trial demonstrate VORANIGO's effectiveness in treating Grade 2 glioma patients, showcasing significant outcomes in tumor reduction and seizure frequency.

Servier Unveils Encouraging Extended Results for VORANIGO Trial in Glioma Treatment #USA #Boston #Servier_Pharmaceuticals #VORANIGO #glioma_treatment

Servier's VORANIGO® Triumphs at 2025 Prix Galien USA Award Ceremony Servier's VORANIGO® (vorasidenib) has won the prestigious 2025 Prix Galien USA Award, recognizing its groundbreaking treatment for glioma patients.

Servier's VORANIGO® Triumphs at 2025 Prix Galien USA Award Ceremony #USA #New_York #Servier #Glioma #VORANIGO

European Commission Approves VORANIGO® as the First Therapy for IDH-Mutant Glioma in Adults The European Commission has approved VORANIGO® as the first targeted treatment for Grade 2 IDH-mutant glioma, marking a breakthrough in precision medicine for this condition.

European Commission Approves VORANIGO® as the First Therapy for IDH-Mutant Glioma in Adults #None #Servier #Glioma #VORANIGO

Servier's VORANIGO® Gains Positive Opinion for Glioma Treatment in the EU Servier celebrates a positive CHMP opinion for VORANIGO®, a groundbreaking therapy for treating Grade 2 IDH-mutant glioma, aiming to improve patient outcomes in the EU.

Servier's VORANIGO® Gains Positive Opinion for Glioma Treatment in the EU #None #Servier #Glioma #VORANIGO

Vorasidenib (Voranigo): What patients need to know? - OncoDaily Learn about Vorasidenib (Voranigo), its uses in cancer, side effects, dosage, administration, and what should patients expect during treatment.

Vorasidenib (Voranigo): What patients need to know?

oncodaily.com/drugs/vorasi...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #Vorasidenib #Voranigo #Astrocytoma #BrainTumors #Drugs #FDAapprovals #Oligodendroglioma

Vorasidenib (Voranigo): Uses in Cancer, Side Effects, Dosage, Expectations, and More - OncoDaily Learn about Vorasidenib (voranigo), its uses in cancer treatment, side effects, dosage, and expectations. It is used for IDH mutated brain tumors.

Vorasidenib (Voranigo): Uses in Cancer, Side Effects, Dosage, Expectations, and More

oncodaily.com/drugs/vorasi...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #Vorasidenib #Voranigo #Astrocytoma #BrainTumor #Drugs #FDAapprovals #Glioma #Oligodendroglioma

Being told you shouldn’t eat broccoli while on a BRAND NEW drug sending me into a rage after I asked my support grp what I can do to lower my liver enzymes…I’m angry “reading” at this point. 🥦🥦🥦 Can’t even focus on the story! #astrocytoma #voranigo #vegetables